查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864772

巨細胞病毒檢測市場按產品、檢測類型、應用、最終用戶和檢體類型分類－2025-2032年全球預測

Cytomegalovirus Tests Market by Product, Test Type, Application, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，巨細胞病毒檢測市場將成長至 11.9201 億美元，複合年成長率為 7.25%。

關鍵市場統計數據
基準年 2024 6.8078億美元
預計年份：2025年 7.3124億美元
預測年份 2032 1,192,010,000 美元
複合年成長率 (%) 7.25%

臨床因素、診斷重點和操作考量之間的策略整合塑造了當代巨細胞病毒檢測和推廣。

隨著診斷技術和診療路徑的不斷發展，巨細胞病毒(CMV) 檢測的臨床和公共衛生重要性日益凸顯。早期準確識別 CMV 感染仍然是新生兒護理、移植患者管理、捐贈者篩檢和產前風險控制的基礎。隨著精準診斷和快速照護現場方案的日益普及，來自臨床、實驗室、研究和商業領域的相關人員必須將技術能力、應用場景優先級和監管要求清晰地整合起來，以指導投資和營運決策。

本概要摘要了目前影響鉅細胞病毒 (CMV) 檢測普及的促進因素和限制因素，重點闡述了檢測性能特徵與實際臨床需求之間的相互作用。它著重介紹了檢測方法的進步、監管和報銷趨勢的影響，以及決定在不同終端用戶環境下檢測普及的營運因素。透過闡述不同檢體類型和臨床應用領域的診斷價值提案，本概述為深入分析變革性轉變、政策影響、細分領域洞察以及為尋求最佳化診斷組合和臨床路徑的決策者提供的實用建議奠定了基礎。

分子診斷和照護現場技術的進步、監管機構對檢驗的重視以及檢體的靈活性，正在如何重塑巨細胞病毒檢測的臨床應用？

鉅細胞病毒 (CMV) 檢測領域正經歷多重變革，這些變革的驅動力包括技術成熟、臨床重點的轉變以及對快速、有效檢測結果日益成長的需求。分子擴增技術在靈敏度和通量方面取得了顯著進步，使得在多種檢體基質中實現早期檢測成為可能，並支持超越傳統血清學檢測的更廣泛的臨床應用場景。同時，照護現場方法和簡化的抗原檢測方式正在融合，以便更貼近患者使用，從而降低了門診和新生兒監護病房及時診斷的門檻，而這些場所對即時做出治療決策至關重要。

監管路徑和實驗室認證標準也在重塑產品的設計和部署。製造商優先考慮可靠的檢驗數據、簡化的使用者工作流程以及與實驗室資訊系統的兼容性，以滿足醫院和參考實驗室的要求。定量結果與定性評估的結合，推動了對能夠支持監測和治療決策的檢測方法的需求，尤其是在移植和周產期護理領域。同時，檢體類型的靈活性（從全血擴展到尿液、唾液和組織檢體）正在拓寬檢測的可能性，並實現微創診斷策略。

這些變化進一步受到醫療保健系統優先事項的強化，這些優先事項強調全面的診斷管理、經濟高效的篩檢通訊協定以及更快的檢測結果出爐時間。隨著技術的融合，成功的產品將在分析性能、易用性、監管合應對力和明確的臨床效用之間取得平衡。最終將形成一個重視互通性、循證聲明以及能夠預見從急診護理到社區醫療保健等不同終端用戶需求的開發策略的診斷環境。

美國近期加徵關稅對巨細胞病毒檢測診斷供應鏈、籌資策略和製造商採購韌性的影響

美國近期實施的關稅政策為全球診斷零件和設備的供應鏈帶來了新的複雜性。進口試劑、儀器零件及相關耗材的關稅增加了製造商和檢測實驗室的到岸成本，促使他們重新評估籌資策略和庫存管理。對於依賴跨境供應鏈的企業而言，這些措施增加了其尋求供應來源多元化和近岸外包方案的必要性，以降低關稅相關成本波動帶來的風險。

為此，製造商和經銷商正在考慮多項措施，包括重新談判供應商合約、增加庫存緩衝以及加快低關稅地區替代供應商的資格認證。實驗室和醫療系統被要求評估總體擁有成本，不僅包括單位成本，還包括物流、海關延誤和潛在的停機風險。採購部門正與臨床相關人員密切合作，確定關鍵檢測的優先順序，並制定產品導入計劃，以在控制財務限制的同時，維持臨床工作的連續性。

政策主導的成本壓力也影響企業在本地製造投資和產品組合的策略決策。一些公司正在對設備設計進行模組化，以便在免稅地區組裝和零件採購；而另一些公司則在尋求許可和契約製造協議，以維持市場進入。因此，競爭優勢越來越依賴供應鏈的韌性以及在波動的貿易環境中維持服務水準協定的能力。對於採購負責人和規劃人員而言，關稅環境凸顯了基於情境的採購規劃以及保持靈活合約的重要性，這些合約能夠適應分銷和生產的變化，同時又不影響臨床運作。

全面的細分分析揭示了產品模式、檢測結果、臨床應用、終端使用者工作流程和檢體基質如何決定診斷價值和市場接受度。

透過分析產品、檢測類型、應用領域、最終用戶和檢體類型，可以揭示鉅細胞病毒 (CMV) 診斷的價值和需求如何隨著臨床環境和技術特性而變化。按產品類型分類，這些診斷包括抗原檢測、核酸增幅檢查和血清學檢測。抗原檢測方法可分為螢光和側向層析法，兩者在速度和靈敏度之間各有優劣。螢光法通常用於尋求更高分析靈敏度的中心實驗室，而側向層析抗原檢測則滿足了快速床邊篩檢的需求。核酸增幅檢查包括數位聚合酵素鏈鎖反應(dPCR)、等溫擴增和即時聚合酵素鏈鎖反應(即時PCR)。數位 PCR 可提供絕對定量，適用於病毒量監測，而等溫擴增法則簡化了儀器操作並可快速獲得結果。然而，由於即時PCR在靈敏度、通量和監管親和性方面達到了平衡，因此仍然是領先的檢測方法。血清學檢測涵蓋化學冷光免疫檢測、酵素免疫分析法和側向流動免疫檢測等形式，提供有關宿主免疫反應的補充資訊，並在篩檢和流行病學監測中發揮核心作用。

按檢測類型分類，定性檢測在初步篩檢和二元診斷決策中仍然至關重要，而定量檢測在監測、風險分層和指導治療管理方面發揮越來越重要的作用。基於應用領域的區分錶明，診斷應用、供體篩檢、產前檢測和一般人群篩檢對檢測特性（例如檢測限、檢體通量和易操作性）的要求各不相同。最終使用者的特徵進一步細分了優先事項：診所和醫院強調快速提供結果和易於整合到臨床工作流程中，診斷實驗室優先考慮高通量自動化和資料管理，而研究機構則專注於檢測的靈活性、分析靈敏度和與下游分析的兼容性。

檢體類型（唾液、組織、尿液、全血）的多樣性為非侵入性檢測途徑提供了可能，但也給檢測方法開發人員帶來了技術挑戰，即如何檢驗不同檢體基質中檢測性能的可比較性。尿液和唾液的採集方法非侵入性，適用於新生兒和門診篩檢；而組織和全血則可能用於需要明確診斷或高靈敏度的應用。基於這些考量，成功的產品策略應將分析優勢與目標使用者的實際操作需求以及每項檢測旨在解決的臨床問題相結合。

診斷環境和基礎設施的區域差異導致了不同的招募路徑

區域趨勢影響著技術應用、報銷機制、實驗室基礎設施和臨床指南，從而為每個地區創造了獨特的策略要務。在美洲，診斷生態系統的特點是實驗室網路完善、分子平台應用廣泛，以及強調對高風險族群進行早期檢測的臨床指南。這些系統重視那些具有臨床效用、擴充性以及與電子健康記錄相容性的檢測方法，同時也要求強大的供應鏈和合規性。

歐洲、中東和非洲地區（EMEA）法規環境和醫療基礎設施的差異，導致了不同的技術應用路徑。一些市場優先考慮使用高通量分子平台進行集中檢測，而其他市場則更重視適用於資源有限環境且經濟高效的分散式篩檢解決方案。在這些地區營運的製造商必須制定靈活的監管策略和分級產品方案，以滿足支付方期望和實驗室能力的差異。

亞太地區正迅速採用創新診斷技術，其臨床需求和採購模式也呈現多樣化的特性。對公共衛生篩檢計畫的投入不斷增加、三級醫療服務的覆蓋範圍不斷擴大以及對本地製造能力的重視，正在塑造該地區的商業性模式。在多個司法管轄區，簡化的法規核准流程和積極的公私合營正在加速技術的應用，而供應鏈在地化的努力也正在影響合約簽訂和定價趨勢。在所有地區，成功的關鍵在於：根據當地實際情況產生證據、與臨床意見領袖密切合作，以及建立能夠適應當地分銷實際情況的物流模式。

現有平台公司、專業創新企業和通路合作夥伴之間的競爭動態和策略行動正在影響檢測套組的可及性和臨床檢驗。

鉅細胞病毒 (CMV) 檢測領域的競爭格局呈現出平台型製造商、專業檢測開發人員和專注於特定臨床應用的創新企業並存的態勢。成熟的診斷公司憑藉其豐富的產品系列、良好的監管記錄和全球分銷網路，提供從高通量檢測系統到照護現場設備等一系列整合解決方案。為了維繫客戶忠誠度並滿足醫院和參考實驗室的需求，這些現有企業正加強對臨床檢驗研究、跨平台相容性和生命週期服務協議的投入。

專業檢測開發人員通常透過技術創新脫穎而出，例如提高靈敏度、簡化分散式檢查流程以及採用專有化學技術來加快檢測結果的出具速度。技術先驅與大型經銷商之間的合作已成為新型檢測方法拓展應用範圍的常見途徑，既能利用現有銷售管道和監管方面的專業知識，又能涵蓋更廣泛的臨床環境。專注於數位化增強和樣本到結果平台的新興參與企業正在重塑人們對定量性能和操作簡便性的預期。

在競爭激烈的市場環境中，服務和支援模式對採購決策的影響日益顯著。買家重視能夠提供安裝、培訓、持續技術支援和完善的品質保證系統的供應商。隨著企業快速提升自身能力並將產品藍圖與臨床需求訊號相契合，與臨床中心簽訂共同開發契約、建立OEM夥伴關係以及進行有針對性的收購等策略措施也變得越來越普遍。對於關注競爭的相關人員，關鍵觀點企業如何將技術主張轉化為檢驗的臨床結果，如何部署可擴展的商業模式，以及如何在各種政策條件下維持供應的連續性。

業界經營團隊可採取切實可行的優先行動，以增強臨床信心、韌性和巨細胞病毒診斷解決方案的採用率

產業領導者可以採取果斷行動，增強臨床對鉅細胞病毒 (CMV) 檢測的信心，加速其普及應用，並建立穩健的供應鏈和商業模式。優先進行強力的臨床檢驗研究，以證明其在預期用途的效用，將有助於增強支付方和醫療服務提供者的信心。使產品設計與目標終端使用者的實際情況相符（例如，最大限度地減少診所的操作時間，確保診斷實驗室的自動化和高通量），將有助於降低推廣應用的障礙，並促進其融入臨床工作流程。

投資於供應鏈韌性至關重要。製造商應透過多元化採購、探索區域製造夥伴關係以及設計可在多個司法管轄區組裝的產品，來降低關稅風險和物流中斷的影響。與臨床意見領袖和公共衛生機構合作，產生符合指南的證據，將有助於將其納入篩檢和監測通訊協定。此外，企業應考慮彈性價格設定和服務捆綁，其中應包含考慮買方整體擁有成本的因素，例如試劑穩定性、儀器運作保證和軟體互通性。

最後，建構能夠實現診斷和臨床管理一體化解決方案的夥伴關係，例如將定量病毒載量報告與病患監測平台整合，可以為終端用戶創造差異化價值。實施這些措施需要明確的優先順序、研發、監管和商業團隊之間的跨職能協作，以及對證據產生和客戶支援基礎設施的持續投入。

一種透明且可重複的研究途徑，結合了嚴謹的二手證據審查、與關鍵相關人員的訪談以及基於情境的檢驗。

本研究採用實證方法，結合系統性的文獻綜述和質性訪談，以確保研究結果的平衡性和可重複性。文獻回顧涵蓋同儕審查的臨床文獻、監管指南文件和技術白皮書，旨在梳理檢測方法的性能特徵、建議的臨床工作流程和檢驗標準。定性訪談則包括對臨床醫生、實驗室主任、採購經理和技術開發人員的結構化訪談，以收集有關技術應用促進因素、營運限制和未滿足需求的第一手資訊。

我們應用了一個分析框架，整合了細分維度和跨區域洞察，以確保技術評估立足於臨床適用性和實驗室實際情況。透過交叉比對設備規格、監管核准和臨床結果研究，三角驗證技術檢驗論點。情境分析用於探索供應鏈中斷和政策變化，而對訪談回應的定性編碼則識別出與易用性、證據預期和服務需求相關的反覆出現的主題。

所有研究結果均經過內部同儕審查和跨部門檢驗，以提高研究的穩健性並減少偏差。調查方法強調資訊來源的透明度和分析過程的可重複性，使相關人員能夠評估我們結論的依據，並根據自身內部情況調整框架。

綜合結論強調，檢驗的創新、營運韌性和實證實施是有效巨細胞病毒診斷策略的支柱。

鉅細胞病毒 (CMV) 診斷處於臨床需求、技術創新和營運要求三者交匯點。分子擴增和即時抗原照護現場技術的進步正在拓展 CMV 檢測的應用情境和案例，尤其是在新生兒、移植患者和孕婦群體中，及時識別 CMV 可顯著影響治療結果。同時，日益嚴格的監管、供應鏈限制和區域差異迫使研發人員和採用者採取靈活且基於實證醫學的策略，優先考慮臨床效用和服務連續性。

決策者應優先考慮產品開發和採購，重點關注其在改善患者管理方面的顯著療效、與現有工作流程的便捷整合以及抵禦政策和物流干擾的能力。這將確保相關人員對診斷技術的投資能夠帶來可衡量的臨床效益和永續的商業性回報。最終，這將形成一個獎勵成熟創新、實用操作以及協作式證據生成和傳播方法的局面。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大多重PCR檢測的應用範圍，此檢測可同時檢測多種病毒病原體，包括鉅細胞病毒（CMV）。
  • 新生兒護理環境中對快速、照護現場的鉅細胞病毒 (CMV) 診斷的需求日益成長，以便能夠快速應對。
  • 整合次世代定序技術，提供全面的鉅細胞病毒基因組分析，用於抗藥性監測。
  • 美國食品藥物管理局 (FDA) 已核准多種高靈敏度免疫檢測，用於早期檢測嬰兒先天性巨細胞病毒感染。
  • 北美和歐洲先天性鉅細胞病毒新生兒篩檢計畫的擴展推動了檢測數量的成長。
  • 成本壓力正在推動全球參考實驗室開發自動化、高通量 CMV 檢測平台。
  • 診斷公司與醫療機構建立策略聯盟，擴大移植患者鉅細胞病毒篩檢

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章巨細胞病毒檢測市場（依產品分類）

  • 抗原檢測
    • 螢光
    • 橫向流動化驗
  • 核酸增幅檢查
    • 數位聚合酵素鏈鎖反應
    • 等溫擴增
    • 即時聚合酵素鏈鎖反應
  • 血清學檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 側向流動免疫檢測

第9章巨細胞病毒檢測市場（依檢測方法分類）

  • 定性測試
  • 定量測試

第10章巨細胞病毒檢測市場（依應用分類）

  • 診斷
  • 捐贈者篩檢
  • 產前檢查
  • 篩檢

第11章巨細胞病毒檢測市場（依最終用戶分類）

  • 診所
  • 診斷實驗室
  • 醫院
  • 研究所

第12章巨細胞病毒檢測市場（依檢體類型分類）

  • 唾液
  • 組織
  • 尿
  • 全血

第13章巨細胞病毒檢測市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章巨細胞病毒檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國巨細胞病毒檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Qiagen NV
    • bioMerieux SA
    • Hologic, Inc.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Becton, Dickinson and Company
    • PerkinElmer, Inc.
Product Code: MRR-6B0EA07975A5

The Cytomegalovirus Tests Market is projected to grow by USD 1,192.01 million at a CAGR of 7.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 680.78 million
Estimated Year [2025] USD 731.24 million
Forecast Year [2032] USD 1,192.01 million
CAGR (%) 7.25%

A strategic synthesis of clinical drivers, diagnostic priorities, and operational considerations shaping contemporary cytomegalovirus testing and adoption

The clinical and public health implications of cytomegalovirus (CMV) testing have intensified as diagnostic technologies and care pathways evolve. Early and accurate identification of CMV infection remains a cornerstone of neonatal care, transplant patient management, donor screening, and prenatal risk mitigation. With growing emphasis on precision diagnostics and rapid point-of-care solutions, stakeholders across clinical, laboratory, research, and commercial domains require a clear synthesis of technological capabilities, use-case priorities, and regulatory expectations to guide investment and operational decisions.

This executive overview synthesizes current drivers and constraints shaping CMV testing adoption, emphasizing the interplay between assay performance characteristics and real-world clinical requirements. It highlights advances in assay modalities, the implications of regulatory and reimbursement trends, and the operational considerations that determine adoption in diverse end-user settings. By clarifying the diagnostic value proposition across sample types and clinical applications, this introduction sets the stage for deeper analysis of transformative shifts, policy impacts, segmentation-specific insights, and practical recommendations for decision-makers seeking to optimize diagnostic portfolios and clinical pathways.

How advances in molecular and point-of-care diagnostics, regulatory emphasis on validation, and sample flexibility are reshaping clinical adoption of cytomegalovirus testing

The CMV testing landscape is undergoing multiple transformative shifts driven by technological maturation, changing clinical priorities, and evolving expectations for rapid, actionable results. Molecular amplification techniques have advanced in sensitivity and throughput, enabling earlier detection in diverse sample matrices and supporting a broader set of clinical scenarios beyond traditional serology. Concurrently, point-of-care modalities and simplified antigen detection formats are converging toward near-patient use, lowering the threshold for timely diagnosis in outpatient clinics and neonatal wards where immediate therapeutic decisions are critical.

Regulatory pathways and laboratory accreditation standards are also reshaping product design and deployment. Manufacturers are prioritizing robust validation data, streamlined user workflows, and compatibility with laboratory information systems to meet hospital and reference laboratory requirements. Integration of quantitative readouts alongside qualitative determinations is increasing demand for assays that can support monitoring and therapeutic decision-making, particularly in transplant medicine and prenatal care. Meanwhile, sample type flexibility-expanding beyond whole blood to include urine, saliva, and tissue specimens-has broadened testing prospects and enabled less invasive diagnostic strategies.

These shifts are reinforced by health system priorities that place a premium on diagnostic stewardship, cost-effective screening protocols, and reduced time-to-result. As technologies converge, successful products will be those that balance analytical performance with usability, regulatory readiness, and clear clinical utility. The cumulative effect is a diagnostic environment that rewards interoperability, evidence-based claims, and development strategies that anticipate diverse end-user needs across acute care and community settings.

Implications of recent United States tariff measures on diagnostic supply chains, procurement strategies, and manufacturer sourcing resilience across cytomegalovirus testing

Recent tariff policies enacted by the United States have introduced an additional layer of complexity to the global supply chain for diagnostic components and instruments. Tariffs on imported reagents, instrument parts, and related consumables can increase landed costs for manufacturers and lab operators, prompting reassessment of sourcing strategies and inventory management. For organizations that rely on cross-border supply chains, these measures have heightened the need for supply diversification and nearshoring options to mitigate exposure to duty-related cost volatility.

In response, manufacturers and distributors have explored multiple mitigations including renegotiating supplier contracts, increasing inventory buffers, and accelerating qualification of alternative vendors in low-tariff jurisdictions. Laboratories and health systems have been compelled to evaluate total cost of ownership rather than unit price alone, factoring in logistics, customs delays, and potential downtime risks. Procurement departments are coordinating more closely with clinical stakeholders to prioritize critical assays and to sequence product rollouts in a manner that preserves clinical continuity while managing fiscal constraints.

Policy-driven cost pressures have also influenced strategic decisions around local manufacturing investment and product configuration. Some firms have opted to modularize instrument design to allow assembly or component sourcing in tariff-exempt locations, while others have pursued licensing or contract manufacturing arrangements to preserve market access. As a result, competitive differentiation is increasingly tied to supply chain resilience and the ability to maintain service level agreements under shifting trade conditions. For buyers and planners, the tariff environment underscores the importance of conducting scenario-based procurement planning and maintaining flexible contracts that can accommodate distribution or production changes without compromising clinical operations.

Comprehensive segmentation analysis revealing how product modality, test output, clinical application, end-user workflows, and sample matrices determine diagnostic value and adoption

Deconstructing CMV diagnostics by product, test type, application, end user, and sample type reveals how value and demand vary across clinical contexts and technology attributes. By product, the landscape includes antigen detection tests, nucleic acid amplification tests, and serological assays. Antigen detection formats differentiate by immunofluorescence and lateral flow approaches, each catering to different speed and sensitivity trade-offs; immunofluorescence assays typically serve centralized labs seeking higher analytical sensitivity while lateral flow antigen tests address rapid near-patient screening needs. Nucleic acid amplification encompasses digital polymerase chain reaction, isothermal amplification techniques, and real-time polymerase chain reaction; digital PCR offers absolute quantification useful for monitoring viral load, isothermal methods facilitate simplified instrumentation and rapid turnaround, and real-time PCR continues to be the workhorse for its balance of sensitivity, throughput, and regulatory familiarity. Serological assays, spanning chemiluminescent immunoassay, enzyme-linked immunosorbent assay, and lateral flow immunoassay formats, provide complementary information on host immune response and are central to screening and epidemiologic surveillance.

When viewed by test type, qualitative assays remain important for initial screening and binary diagnostic decisions, while quantitative assays increasingly inform monitoring, risk stratification, and therapeutic management. Application-driven differentiation shows that diagnostic use, donor screening, prenatal testing, and general population screening each place distinct demands on assay attributes such as limit of detection, sample throughput, and ease of use. End-user dynamics further stratify priorities: clinics and hospitals emphasize rapid turnaround and ease of integration into clinical workflows, diagnostic laboratories prioritize high-throughput automation and data management, and research institutes focus on assay flexibility, analytical sensitivity, and compatibility with downstream analyses.

Sample type variation-saliva, tissue, urine, and whole blood-creates opportunities for less invasive testing pathways as well as technical challenges for assay developers in validating performance equivalently across matrices. Urine and saliva offer noninvasive collection suited to neonatal and outpatient screening, whereas tissue and whole blood may be required for definitive diagnosis or for applications demanding high sensitivity. Across these axes, successful product strategies are those that align analytical strengths with the operational realities of target users and the clinical questions each assay seeks to answer.

Regional diagnostic landscapes and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated adoption pathways

Regional dynamics shape technology adoption, reimbursement practices, laboratory infrastructure, and clinical guidelines, creating distinct strategic imperatives across geographies. In the Americas, diagnostic ecosystems are characterized by well-established laboratory networks, adoption of molecular platforms, and clinical guidelines that favor early detection in high-risk populations. These systems reward assays that demonstrate clinical utility, scalability, and compatibility with electronic health records, while also demanding resilient supply chains and regulatory compliance.

In Europe, the Middle East & Africa region, heterogeneity in regulatory environments and healthcare infrastructure leads to varied adoption pathways. Some markets prioritize centralized testing with high-throughput molecular platforms, whereas others emphasize cost-effective, decentralized screening solutions that can function in lower-resource settings. Manufacturers pursuing these geographies must design flexible regulatory strategies and tiered product offerings to address divergent payer expectations and laboratory capabilities.

The Asia-Pacific region exhibits rapid uptake of innovative diagnostic technologies alongside diverse clinical needs and procurement models. Growing investments in public health screening programs, expanding access to tertiary care, and a strong emphasis on local manufacturing capacity shape commercial approaches. In several jurisdictions, expedited regulatory pathways and active public-private partnerships accelerate adoption, while supply chain localization efforts influence contractual and pricing dynamics. Across all regions, success depends on tailored evidence-generation, close engagement with clinical opinion leaders, and logistical models that account for regional distribution realities.

Competitive dynamics and strategic behaviors among platform incumbents, specialized innovators, and channel partners shaping assay availability and clinical validation

Competitive activity in the CMV testing arena reflects a mix of platform-focused manufacturers, specialized assay developers, and emerging innovators targeting niche clinical applications. Established diagnostic firms tend to compete on portfolio breadth, regulatory track record, and global distribution networks, offering integrated solutions that span high-throughput laboratory systems to point-of-care instrumentation. These incumbents invest in clinical validation studies, cross-platform compatibility, and lifecycle service agreements to maintain customer lock-in and to support hospital and reference laboratory requirements.

Specialized assay developers often differentiate through technical innovation such as enhanced sensitivity, simplified workflows for decentralized testing, or proprietary chemistries that reduce time-to-result. Partnerships between technology pioneers and larger distributors have become a common path to scale, enabling novel assays to reach broader clinical settings while leveraging established sales channels and regulatory expertise. New entrants focused on digital amplification methods or sample-to-answer platforms are reshaping expectations for quantitative performance and operational simplicity.

Across competitive dynamics, service and support models increasingly influence procurement decisions. Buyers value vendors that can provide installation, training, ongoing technical support, and robust quality assurance programs. Strategic behaviors such as co-development agreements with clinical centers, OEM partnerships, and targeted acquisitions are prevalent as firms seek to bolster capabilities quickly and to align product roadmaps with clinical demand signals. For stakeholders monitoring competitiveness, the critical lens is on how firms translate technical claims into validated clinical outcomes, deploy scalable commercial models, and maintain supply continuity under varied policy conditions.

Practical and prioritized actions for industry executives to enhance clinical credibility, resilience, and adoption of cytomegalovirus diagnostic solutions

Industry leaders can act decisively to capture clinical trust, accelerate adoption, and build resilient supply and commercial models in CMV testing. Prioritizing robust clinical validation studies that demonstrate actionable utility across intended applications will strengthen payer and provider confidence. Aligning product design with the operational realities of target end users-such as minimizing hands-on time for clinics or ensuring automation and throughput for diagnostic laboratories-will reduce barriers to adoption and support integration into clinical workflows.

Investing in supply chain resilience is essential; manufacturers should diversify sourcing, consider regional manufacturing partnerships, and design products that can be assembled across multiple jurisdictions to mitigate tariff exposure and logistical disruption. Collaborating with clinical thought leaders and public health authorities to generate guideline-aligned evidence will facilitate inclusion in screening and monitoring protocols. Additionally, companies should evaluate flexible pricing and service bundles that reflect total cost of ownership considerations for buyers, including reagent stability, instrument uptime guarantees, and software interoperability.

Finally, fostering partnerships that enable combined diagnostic and clinical management solutions-such as integrating quantitative viral load reporting with patient monitoring platforms-can create differentiated value for end users. Executing on these actions will require clear prioritization, cross-functional coordination between R&D, regulatory, and commercial teams, and disciplined investment in evidence generation and customer support infrastructure.

Transparent, reproducible research approach combining rigorous secondary evidence review with primary stakeholder interviews and scenario-based validation

This research utilized an evidence-driven methodology combining systematic secondary literature review with primary qualitative interviews to ensure balanced and reproducible findings. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers to map assay performance characteristics, recommended clinical workflows, and validation standards. Primary research included structured interviews with clinicians, laboratory directors, procurement managers, and technology developers to capture firsthand perspectives on adoption drivers, operational constraints, and unmet needs.

Analytical frameworks were applied to synthesize insights across segmentation axes and geographies, ensuring that technology assessments were grounded in clinical applicability and laboratory realities. Triangulation techniques validated claims by cross-referencing instrument specifications, regulatory approvals, and clinical outcome studies. Scenario analysis was used to explore supply chain disruptions and policy shifts, while qualitative coding of interview responses identified recurring themes related to usability, evidence expectations, and service requirements.

All findings were subjected to internal peer review and cross-functional validation to enhance robustness and to reduce bias. The methodology emphasized transparency in source attribution and reproducibility of analytic steps, enabling stakeholders to assess the evidentiary basis for conclusions and to adapt frameworks for internal use.

Consolidated conclusions emphasizing validated innovation, operational resilience, and evidence-driven adoption as the pillars for effective cytomegalovirus diagnostic strategies

CMV diagnostics occupy a dynamic intersection of clinical need, technological innovation, and operational imperatives. Advances in molecular amplification and point-of-care antigen detection are expanding the settings and use cases where timely CMV identification can materially influence outcomes for neonates, transplant recipients, and pregnant patients. At the same time, regulatory rigor, supply chain constraints, and regional heterogeneity demand that developers and adopters pursue evidence-driven, flexible strategies that prioritize clinical utility and service continuity.

Decision-makers should orient product development and procurement around demonstrable improvements in patient management, ease of integration into existing workflows, and resilience against policy- or logistics-driven disruptions. By doing so, stakeholders can ensure that investments in diagnostics translate into measurable clinical benefits and sustainable commercial returns. The net effect is a landscape that rewards validated innovation, operational pragmatism, and collaborative approaches to evidence generation and distribution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of multiplex PCR assays enabling simultaneous detection of multiple viral pathogens including CMV
  • 5.2. Rising demand for rapid point of care CMV diagnostics to facilitate timely management in neonatal care settings
  • 5.3. Integration of next generation sequencing techniques to provide comprehensive CMV genome analysis for drug resistance monitoring
  • 5.4. Emerging FDA clearances of highly sensitive immunoassays for early detection of congenital cytomegalovirus infections in infants
  • 5.5. Growing implementation of newborn screening programs for congenital CMV in North America and Europe driving test volumes
  • 5.6. Cost pressure leading to development of automated high throughput CMV testing platforms in reference laboratories worldwide
  • 5.7. Strategic collaborations between diagnostic companies and healthcare providers to expand CMV screening in transplant patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cytomegalovirus Tests Market, by Product

  • 8.1. Antigen Detection Test
    • 8.1.1. Immunofluorescence Assay
    • 8.1.2. Lateral Flow Assay
  • 8.2. Nucleic Acid Amplification Test
    • 8.2.1. Digital Polymerase Chain Reaction
    • 8.2.2. Isothermal Amplification
    • 8.2.3. Real Time Polymerase Chain Reaction
  • 8.3. Serological Assay
    • 8.3.1. Chemiluminescent Immunoassay
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Lateral Flow Immunoassay

9. Cytomegalovirus Tests Market, by Test Type

  • 9.1. Qualitative
  • 9.2. Quantitative

10. Cytomegalovirus Tests Market, by Application

  • 10.1. Diagnostic
  • 10.2. Donor Screening
  • 10.3. Prenatal Testing
  • 10.4. Screening

11. Cytomegalovirus Tests Market, by End User

  • 11.1. Clinic
  • 11.2. Diagnostic Laboratory
  • 11.3. Hospital
  • 11.4. Research Institute

12. Cytomegalovirus Tests Market, by Sample Type

  • 12.1. Saliva
  • 12.2. Tissue
  • 12.3. Urine
  • 12.4. Whole Blood

13. Cytomegalovirus Tests Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cytomegalovirus Tests Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cytomegalovirus Tests Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Qiagen N.V.
    • 16.3.4. bioMerieux SA
    • 16.3.5. Hologic, Inc.
    • 16.3.6. Siemens Healthineers AG
    • 16.3.7. Thermo Fisher Scientific Inc.
    • 16.3.8. Danaher Corporation
    • 16.3.9. Becton, Dickinson and Company
    • 16.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MIL